Article

Ocular bacterial treatment in development

Alameda, CA-InSite Vision Inc. and Bausch & Lomb have signed a licensing agree-ment to develop InSite's product ISV-403 for the treatment of ocular bacterial infections.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Content
Outlook Therapeutics stock undergoes 1-for-20 reverse stock split
March 14th 2024

Outlook Therapeutics stock undergoes 1-for-20 reverse stock split

Planning for financial safety in an uncertain year
October 31st 2020

Planning for financial safety in uncertain times

©utah51 / stock.adobe.com
April 26th 2023

The ins and outs of treating ‘financial cataracts’

Over time, markets have proved positive and resilient
March 17th 2023

Over time, markets have proved positive and resilient

Are there alternative opportunities in volatile markets?
October 28th 2022

Are there alternative opportunities in volatile markets?

The sword and shield of investing
May 20th 2022

The sword and shield of investing

© 2025 MJH Life Sciences

All rights reserved.